Serum cytokine profiles in Behçet's disease: Is there a role for IL-15 in pathogenesis?

Immunology Letters

Volumn 121, Issue 1, 2008, Pages 7-12

  Curnow, S J ^a   Pryce, K ^a   Modi, N ^b   Knight, B ^b   Graham, E M ^b   Stewart, J E ^c   Fortune, F ^c   Stanford, M R ^b   Murray, P I ^a   Wallace, G R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Behcet's disease; Cytokines; IL 15

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 8; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; APHTHOUS STOMATITIS; ARTICLE; BEHCET DISEASE; DISEASE ACTIVITY; FEMALE; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL;

BEHCET SYNDROME; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-15; MALE; STOMATITIS, APHTHOUS;

EID: 54049124064     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2008.07.009     Document Type: Article

References (38)

1. Verity D.H., Wallace G.R., Vaughan R.W., and Stanford M.R. Behcet's disease; from hippocrates to the 21st century. Br J Ophthalmol 87 (2003) 1175-1183
2. Direskeneli H. Behcet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 60 (2001) 996-1002
3. Frassinito M.A., Dammaco R., Cafforio P., and Dammaco F. Th1 polarization of the immune response in Behcet's disease: putative pathogenic role of interleukin-12. Arthritis Rheum 42 (1999) 1967-1974
4. Li B., Yang P., Zhou H., Zhang Z., Xie E., Hwang X., et al. T-bet expression is upregulated in active Behcet's disease. Br J Ophthalmol 87 (2003) 1264-1267
5. Yamakawa Y., Sugita Y., Nagatani T., Takahashi S., Yamakawa T., Tanaka S., et al. Interleukin-6 (IL-6) in patients with Behçet's disease. J Dermatol Sci 11 (1996) 189-193
6. + T cells. J Exp Med 185 (1997) 461-469
7. + T cells into the Th1 cytokine effector pathway during T-cell division following stimulation in Behcet's disease. Rheumatology 43 (2004) 843-851
8. Hamzaoui K., Hamzaoui A., Guemira F., Bessioud M., Hamza M., and Ayed K. Cytokine profile in Behcet's disease patients. Scand J Rheumatol 31 (2002) 205-210
9. Sahin S., Akoglu T., Direskeneli H., Sen L.S., and Lawrence R. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet's disease. Ann Rheum Dis 55 (1996) 128-133
10. Eksioglu-Demiralp E., Direskeneli H., Kibaroglu A., Yavuz S., Ergun T., and Akoglu T. Neutrophil activation in Behcet's disease. Clin Exp Rheumatol 19 (2001) S19-24
11. Kawakami T., Ohashi S., Kawa Y., Takahama H., Ito M., Soma Y., et al. Elevated serum G-CSF levels in patients with active phase of Sweet syndrome and patients with active Behcet's disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol 140 (2004) 570-574
12. Wang L.M., Kitteringham N., Mineshita S., Wang J.Z., Nomura Y., Koike Y., et al. The demonstration of serum interleukin-8 and superoxide dismutase in Adamantiades-Behcet's disease. Arch Dermatol Res 298 (1997) 444-447
13. Zouboulis C.C., Katsantonis J., Ketteler R., Treudler R., Kaklamani E., Homemann S., et al. Adamantiades-Behcet's disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol 292 (2000) 279-284
14. Katsantonis J., Adler Y., Orfanos C.E., and Zouboulis C.C. Adamantiades-Behcet's disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 201 (2000) 37-39
15. Evereklioglu C., Er H., Turkoz Y., and Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6 and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease. Mediat Inflamm 11 (2002) 87-93
16. Mantas C., Direskeneli H., Oz D., Yavuz S., and Akoglu T. IL-8 producing cells in patients with Behcet's disease. Clin Exp Rheumatol 18 (2000) 249-251
17. International Study Group for Behcet's disease. Criteria for the diagnosis of Behcet's disease. Lancet 335 (1990) 1070-1080
18. Gilworth G., Chamberlain M.A., Bhakta B., Haskard D., Silman A., and Tennant A. Development of the BD-QoL: a quality of life measure specific to Behcet's disease. J Rheumatol 31 (2004) 931-937
19. Arnott I.D., Watts D., and Satsangi J. Azathioprine and anti-TNF therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol Res 47 (2003) 1-10
20. Miller E.J., and Brelsford W.G. Interleukin-8: the major neutrophil chemotaxin in a case of psuedogout. J Rheumatol 20 (1993) 1250-1252
21. + T cells are cytotoxic effectors in patients with active Behcet's uveitis. J Immunol 175 (2005) 6133-6142
22. Gracia V.E., Jullien D., Song M., Uyemura K., Shuai K., Mortia C.T., et al. IL-15 enhances the response of human γδ T cells to nonpeptide microbial antigens. J Immunol 160 (1998) 4322-4329
23. + T cells and natural killer cells in Behcet's disease. J Rheumatol 19 (1992) 588-592
24. Freysdottir J., Lau S.H., and Fortune F. Gamma-delta+ T cells and natural killer cells in Behcet's disease(BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 118 (1999) 451-457
25. Banks I., Duvdevani M., and Livneh A. Expansion of γδ T cells in Behcet's disease: role of disease activity and microbial flora in oral ulcers. J Lab Clin Med 141 (2003) 33-40
26. + γδ T cells to Streptococcus sanguis in patients with Behcet's disease. Ocular Immunol Inflamm 6 (1998) 139-144
27. Yamashita N., Kaneoka H., Kaneoka S., Takeno M., Oneda K., Koizumi H., et al. Role of γδ T lymphocytes in the development of Behcet's disease. Clin Exp Immunol 107 (1997) 241-247
28. Verjans G.M., van Hagen P.M., van der Kooi A., Osterhaus A.D., and Baarsma G.S. Vγ9Vδ2 T cells recovered from eyes of patients with Behcet's disease recognize non-peptide prenyl pyrophosphate antigens. J Neuroimmunol 130 (2002) 46-54
29. Ahn J.K., Yu H.G., Chung H., and Park Y.G. Intraocular cytokine environment in active Behcet's uveitis. Am J Ophthalmol 142 (2006) 429-434
30. Hamzaoui K., Hamzaoui A., Ghorbel I., Khanfir M., and Houman H. Levels of IL-15 in serum and cerebrospinal fluid of patients with Behcet's disease. Scand J Immunol 64 (2006) 655-660
31. Gonzalez-Alvaro I., Ortiz A.M., Garcia-Vicuna R., Balsa A., Pascual-Salcedo D., and Laffon A. Increased serum levels of interleukin-15 in rheumatoid arthritis with long-term disease. Clin Exp Rheumatol 21 (2003) 639-642
32. Neely G.G., Epelman S., Ma L.L., Colarusso P., Howlett C.J., Amankwah E.K., et al. Monocyte surface-bound IL-15 can function as an activating receptor and participate in reverse signalling. J Immunol 172 (2004) 4225-4234
33. Ahmad T., Wallace G.R., James T., Neville M., Bunce M., Mulcahy-Hawes K., et al. Behcet's disease and TNF: a missing genetic link. Arthritis Rheum 48 (2003) 807-813
34. Verity D.H., Wallace G.R., Vaughan R.W., et al. HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behcet's disease. Tissue Ageing 54 (1999) 264-272
35. Mochizuki M., Morita E., Yamamoto S., and Yamana S. Characteristics of T cell lines established from skin lesions of Behcet's disease. J Dermatol Sci 15 (1997) 9-13
36. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374 (2003) 1-20
37. Misumi M., Hagiwara E., Takeno M., Takeda Y., Inoue Y., Tsuji T., et al. Cytokine profile in patients with Behcet's disease treated with infliximab. Cytokine 24 (2003) 210-218
38. Kotter I., Koch S., Vonthein R., Ruckwaldt U., Amberger M., Gunaydin I., et al. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behcet's disease treated with human recombinant interferon-alpha2a. Results of an open study and a review of the literature. Clin Exp Rheumatol 23 Suppl. 38 (2005) S20-26